Clinical validity of a DPYD‐based pharmacogenetic test to predict severe toxicity to fluoropyrimidines

E-ISSN： 1097-0215|137|12|2971-2980

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.137, Iss.12, 2015-12, pp. : 2971-2980

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Response to “A Case of 5‐FU‐Related Severe Toxicity Associated With the P.Y186C DPYD Variant”

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 137-137

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Case of 5‐FU‐Related Severe Toxicity Associated with the p.Y186C DPYD Variant

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 136-136

John Wiley & Sons Inc

Access to resources Recommend Favorite

Measurement of DPD and TS Transcripts Aimed to Predict Clinical Benefit from Fluoropyrimidines: Confirmation of the Trend in Russian Colorectal Cancer Series and Caution Regarding the Gene Referees

Oncology Research and Treatment, Vol. 30, Iss. 6, 2007-05 ,pp. : 295-300

Karger

Access to resources Recommend Favorite

The Tyneside Pegboard Test: balancing clinical utility against ecological validity

DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, Vol. 60, Iss. 3, 2018-03 ,pp. : 224-224

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical pharmacy consultation for pharmacogenetic testing

By Shin Jaekyu Kayser Steven R

Personalized Medicine, Vol. 6, Iss. 2, 2009-03 ,pp. : 183-192

Future Medicine

Access to resources Recommend Favorite